Quantcast
Home > Quotes > SYNH
SYNH

Syneos Health, Inc. Class A Common Stock (SYNH) Quote & Summary Data

$47.64
*  
0.34
0.71%
Get SYNH Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading SYNH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SYNH Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
59.5
Today's High / Low
$ 48.5325 / $ 46.10
Share Volume
419,792
50 Day Avg. Daily Volume
559,975
Previous Close
$ 47.98
52 Week High / Low
$ 53.95 / $ 31.10
Market Cap
4,917,682,734
P/E Ratio
NE
Forward P/E (1y)
19.21
Earnings Per Share (EPS)
$ -0.35
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.06

Intraday Chart

Shares Traded

Share Volume:
419,792
50 Day Avg. Daily Volume:
559,975

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
19.21
Earnings Per Share (EPS):
$ -0.35

Trading Range

The current last sale of $47.64 is 53.18% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 48.5325 $ 53.95
 Low: $ 46.10 $ 31.10

Company Description (as filed with the SEC)

Overview We are a leading global biopharmaceutical services organization providing product development and commercial solutions through our clinical end-to-end contract research organization ("CRO") and contract commercial organization ("CCO"). We offer both standalone and integrated biopharmaceutical solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. Our ability to achieve end-to-end solutions is based on our biopharmaceutical acceleration model ("BAM") where we synchronize our clinical and commercial capabilities - sharing knowledge, data, and insights. Our customers include large and small to mid-sized companies in the biopharmaceutical, biotechnology, and medical device industries. Our revenue is derived through a broad suite of services designed to enhance our customers' ability to successfully develop, launch, and market products.  ... More ...  


Risk Grade

Where does SYNH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 48.31
Open Date:
Dec. 10, 2018
Close Price:
$ 47.64
Close Date:
Dec. 10, 2018

Consensus Recommendation

Analyst Info